Regulation of protein citrullination through p53/PADI4Network in DNA damage response

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8761-8769

  Tanikawa, Chizu ^a   Ueda, Koji ^b   Nakagawa, Hidewaki ^b   Yoshida, Nobuaki ^a   Nakamura, Yusuke ^a   Matsuda, Koichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; NUCLEOPHOSMIN; PEPTIDYLARGININE DEIMINASE TYPE 4; PROTEIN ARGININE DEIMINASE; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR CELL;

BLOTTING, WESTERN; CELL LINE; CITRULLINE; DNA DAMAGE; HUMANS; HYDROLASES; IMMUNOPRECIPITATION; MASS SPECTROMETRY; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 72249096427     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2280     Document Type: Article

References (35)

1. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-3555 (Pubitemid 24299821)
2. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992;4:1-15.
3. Chao C, Hergenhahn M, Kaeser MD, et al. Cell typeand promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem 2003;278: 41028-41033 (Pubitemid 37280926)
4. Rahman-Roblick R, Roblick UJ, Hellman U, et al. p53 targets identified by protein expression profiling. Proc Natl Acad Sci U S A 2007;104:5401-5406
5. Suzuki A, Yamada R, Yamamoto K. Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann N Y Acad Sci 2007;1108:323-339 (Pubitemid 47528745)
6. Cuthbert GL, Daujat S, Snowden AW, et al. Histone deimination antagonizes arginine methylation. Cell 2004;118:545-553 (Pubitemid 39179708)
7. Wang Y, Wysocka J, Sayegh J, et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004;306:279-283 (Pubitemid 39336873)
8. de Seze J, Dubucquoi S, Lefranc D, et al. IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. J Neuroimmunol 2001;117:149-155 (Pubitemid 32595502)
9. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-163 (Pubitemid 30368225)
10. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-243 (Pubitemid 32223739)
11. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4:87-93. (Pubitemid 34257342)
12. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34:395-402. (Pubitemid 36935332)
13. Thompson PR, Fast W. Histone citrullination by protein arginine deiminase: is arginine methylation a green light or a roadblock? ACS Chem Biol 2006;1:433-441
14. Hagiwara T, Nakashima K, Hirano H, Senshu T, Yamada M. Deimination of arginine residues in nucleophosmin/ B23 and histones in HL-60 granulocytes. Biochem Biophys Res Commun 2002;290:979-983 (Pubitemid 34687458)
15. Ishigami A, Kuramoto M, Yamada M, Watanabe K, Senshu T. Molecular cloning of two novel types of peptidylarginine deiminase cDNAs from retinoic acid-treated culture of a newborn rat keratinocyte cell line. FEBS Lett 1998;433:113-118 (Pubitemid 28386743)
16. Watanabe K, Akiyama K, Hikichi K, Ohtsuka R, Okuyama A, Senshu T. Combined biochemical and immunochemical comparison of peptidylarginine deiminases present in various tissues. Biochim Biophys Acta 1988;966:375-383
17. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 2008;27:1562-1571 (Pubitemid 351347882)
18. Tanikawa C, Matsuda K, Fukuda S, Nakamura Y, Arakawa H. p53RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 2003;5:216-223 (Pubitemid 36322248)
19. Tanikawa C, Furukawa Y, Yoshida N, Arakawa H, Nakamura Y, Matsuda K. XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway. Oncogene 2009;28:3081-3092
20. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102:849-862
21. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 2002;62: 2883-2889 (Pubitemid 34525775)
22. Muramatsu M, Onishi T. Isolation and purification of nucleoli and nucleolar chromatin from mammalian cells. Methods Cell Biol 1978;17:141-161
23. Senshu T, Sato T, Inoue T, Akiyama K, Asaga H. Detection of citrulline residues in deiminated proteins on polyvinylidene difluoride membrane. Anal Biochem 1992;203:94-100.
24. Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M. Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol 2004;11: 777-783
25. Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 2003;22:6068-6077 (Pubitemid 37463250)
26. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002;99:409-426 (Pubitemid 34533074)
27. Nozawa Y, Van Belzen N, Van der Made AC,DinjensWN, Bosman FT. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 1996;178:48-52. (Pubitemid 26053395)
28. Tsui KH, Cheng AJ, Chang PL, Pan TL, Yung BY. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 2004;64:839-844 (Pubitemid 39446085)
29. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-266 (Pubitemid 40110814)
30. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005;437:147-153 (Pubitemid 41613442)
31. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000;275:24451-24457 (Pubitemid 30626537)
32. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/ B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103:127-140
33. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002;4:529-533
34. Korgaonkar C, Hagen J, Tompkins V, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005;25:1258-1271
35. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493-505.